Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Duke Human Vaccine Institute, Durham, North Carolina, USA. mattia.bonsignori@duke.edu
Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2] conformational specificity and CD4-binding site specificity, respectively) that recapitulate 95% of CH0219 serum neutralization breadth. These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities.
Images from this publication.See all images (3)Free text
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on